FF 10501

Drug Profile

FF 10501

Alternative Names: FF 10501 01; FF-10501

Latest Information Update: 30 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FUJIFILM Holdings Corporation
  • Developer FUJIFILM Holdings Corporation; Strategia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Cell differentiation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 30 May 2017 FF 10501 is still in phase I trials for Myelodysplastic-syndromes in Japan (PO, Tablet)
  • 28 Apr 2017 Fujifilm completes a phase I trial in Myelodysplastic syndromes in Japan (PO) (JapicCTI132093)
  • 03 Dec 2016 Pharmacokinetics, pharmacodynamics, safety and efficacy data from a phase I/II trial in Acute Myeloid Leukemia and Myelodysplastic syndromes presented 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top